Latest news with #RichardRoxburgh
Sydney Morning Herald
27-05-2025
- Entertainment
- Sydney Morning Herald
‘Not as snobby as it might sound': Silvia Colloca on why cooking pasta al dente matters
Italian-Australian TV personality and cookbook author Silvia Colloca makes fresh pasta four days a week at the northern beaches Sydney home she shares with her husband, actor Richard Roxburgh, and their three children. But when she's eating out, it's almost the last thing she'd order – unless it meets her strict standards. 'It's imperative the pasta is not overcooked,' says Colloca, who will share a heaped helping of her cooking knowledge in the third series of Silvia's Italian Masterclass when it airs on Network Ten later this year. 'The concept of al dente [resistance to the tooth] matters to Italians and it matters to me. It's more important than you think and not as snobby as it might sound. 'It mostly applies to dry pasta,' she says. 'As a rule of thumb, if the packet says 11 minutes, take it out after 9 or 10 minutes because it continues to cook with the residual heat.'
The Age
27-05-2025
- Entertainment
- The Age
‘Not as snobby as it might sound': Silvia Colloca on why cooking pasta al dente matters
Italian-Australian TV personality and cookbook author Silvia Colloca makes fresh pasta four days a week at the northern beaches Sydney home she shares with her husband, actor Richard Roxburgh, and their three children. But when she's eating out, it's almost the last thing she'd order – unless it meets her strict standards. 'It's imperative the pasta is not overcooked,' says Colloca, who will share a heaped helping of her cooking knowledge in the third series of Silvia's Italian Masterclass when it airs on Network Ten later this year. 'The concept of al dente [resistance to the tooth] matters to Italians and it matters to me. It's more important than you think and not as snobby as it might sound. 'It mostly applies to dry pasta,' she says. 'As a rule of thumb, if the packet says 11 minutes, take it out after 9 or 10 minutes because it continues to cook with the residual heat.'
Daily Mail
25-05-2025
- Entertainment
- Daily Mail
Cate Blanchett looks glamorous in a dramatic black gown with ruffled cape as she attends the closing ceremony of the 78th Cannes Film Festival
Famed Australian actress Cate Blanchett turned heads as she hit the red carpet for the closing ceremony of the 78th Cannes Film Festival on Saturday. The 56-year-old Oscar winner looked glamorous in a sleeveless black custom Louis Vuitton gown, which featured a long train and a cape of ruffled chiffon. Wearing her trademark blonde locks in an eye-catching swept back hair-do, the Hollywood great waved and smiled as she entered the auditorium to present the Cannes' top prize the Palm d'Or. The Melbourne-born star accessorised with an elegant set of diamond and ruby earrings and completed her look with an understated soft glam makeup. Cate was later seen on stage smiling broadly as she handed over the coveted prize alongside French actress Juliette Binoche to acclaimed Iranian filmmaker Jafar Panahi for his searing drama It Was Just an Accident. From A-list scandals and red carpet mishaps to exclusive pictures and viral moments, subscribe to the DailyMail's new showbiz newsletter to stay in the loop. It comes after Cate's long-time co-star Richard Roxburgh cheekily revealed she will happily 'make a complete idiot of herself' when on set. The 63-year-old Australian actor recently discussed his experiences working with Cate on the A Life of Greatness podcast last month. 'Cate is incredibly brave. She is so happy to make a complete idiot of herself. She will do things in the rehearsal room,' Richard began. 'I remember we were doing a play at the Sydney Theatre Company. She would do things on the rehearsal floor. 'You just think "Oh my God". Totally shameless and unguarded.' His remarks coincide with Cate's reputation for being a bold actress who works extremely hard to get into character. Richard has co-starred in three movies with Cate, including the 1997 drama film Oscar and Lucinda, and also appeared on stage with her in several productions. In 2017, they were co-stars in the Broadway show The Present, which is an adaption of an Anton Chekhov play, adapted by Cate's husband Andrew Upton. The pair celebrated their time together on the show with the unveiling of their caricatures at the world-famous Sardi's Restaurant in New York City. It follows reports that Cate has plans to retire from showbusiness, after decades in the industry. The Oscar-winning actress hesitated about her job title during a recent interview with Radio Times and explained: 'It's because I'm giving up [acting]. My family roll their eyes every time I say it, but I mean it. I am serious.' The Melbourne-born actress insisted she still had 'a lot of things I want to do with my life'. The Little Fish star, who recently starred in an adaptation of Chekov's The Seagull at the Barbican, London, did not give a time frame for her departure from the entertainment industry. But it is not the first time that she has threatened to quit her career despite international acclaim. Cate told Vanity Fair in 2023 that she has often toyed with the idea of walking away from her acting work. Despite her latest declaration, the Lord of the Rings star recently featured in her first radio play on Radio 4, in a 90-minute monologue titled The Fever. Written by Wallace Shawn, Cate played an unnamed traveller who fell ill in a foreign country riven by civil war.
Yahoo
26-03-2025
- Business
- Yahoo
Epicrispr Biotechnologies Secures $68 Million Series B to Initiate Clinical Trial for First-in-Class Disease-Modifying Epigenetic Neuromuscular Therapy for FSHD
- Financing led by Ally Bridge Group, with participation from SOLVE FSHD, a venture philanthropy organization - Lead program, EPI-321, is the first clinical application of epigenetic modulation in neuromuscular diseases, with a first-in-human trial in New Zealand to commence in 2025 as part of a broader global clinical strategy SOUTH SAN FRANCISCO, Calif., March 26, 2025--(BUSINESS WIRE)--Epicrispr Biotechnologies, a biotechnology company focused on developing curative therapies, today announced it has secured $68 million in the first close of its Series B financing. The proceeds will support the clinical development of EPI-321, a first-in-class, disease-modifying therapy for facioscapulohumeral muscular dystrophy (FSHD), a genetic neuromuscular disease. The Series B financing was led by Ally Bridge Group, with participation from SOLVE FSHD, the venture philanthropy organization founded by Chip Wilson, founder of Lululemon Athletica and FSHD patient, along with other new and existing investors. The financing will support Epicrispr's upcoming clinical trial of EPI-321, as well as continued advancement of the company's broader pipeline. Epicrispr also announced clinical trial application (CTA) approval from New Zealand's Medsafe to initiate a first-in-human trial of EPI-321, the first epigenetic therapy to enter the clinic for a neuromuscular disease. The study is expected to begin in 2025, and will evaluate the safety, tolerability, pharmacodynamics, and biological activity of a single intravenous dose of EPI-321 in adults with FSHD. "FSHD is one of the most common adult muscular dystrophies, with estimates of up to 1 million patients affected worldwide. But patients have no disease-modifying therapy for this progressive disease," said Dr. Richard Roxburgh, Associate Professor of Medicine at the University of Auckland and principal investigator for the EPI-321 clinical trial, which is planned to be conducted in partnership with Pacific Clinical Research Network, a leading clinical research center in New Zealand. "We look forward to advancing this clinical trial which could, with a single treatment, permanently address the disease's underlying cause, and are hopeful that it will pave the way for new standards for therapies in genetic diseases." EPI-321 is an investigational one-time gene-modulating therapy designed to silence aberrant expression of DUX4, a gene that is incorrectly activated in FSHD and leads to progressive muscle degeneration. Delivered systemically via a clinically validated AAV vector, EPI-321 has demonstrated robust suppression of DUX4 expression and protection of muscle tissue in preclinical models. EPI-321 has received FDA Fast Track, Rare Pediatric Disease, and Orphan Drug designations. "We are developing a first-in-class, one-time epigenetic therapy that targets the genetic root cause of FSHD," said Amber Salzman, Ph.D., CEO, Epicrispr Biotechnologies. "The Series B financing and regulatory clearance to begin our first-in-human trial marks a pivotal milestone as we become a clinical-stage company. With a strong investor syndicate and recent FDA designations recognizing EPI-321's potential, our team is laser-focused on advancing EPI-321 into the clinic to provide a much-needed therapy to patients and families in desperate need." "With a robust body of data validating the potential of EPI-321 and the GEMS platform broadly, Epicrispr has shown itself to be a leading epigenetic editing company," said Andrew Lam, Pharm.D., Managing Director, Head of Biotech Private Equity, Ally Bridge Group. "We are proud to lead this investment in Epicrispr's future, and we look forward to partnering with their leadership to support their continued success." "As someone living with FSHD, I know the devastating impact of this disease and the urgent need for treatments that target its root cause," said Chip Wilson, founder and Chairman of SOLVE FSHD. "We commend Epicrispr's commitment in advancing EPI-321 for FSHD and are glad to be part of this financing to support its transition to the clinic." Concurrent with the funding, Epicrispr has expanded its Board of Directors with the addition of Andrew Lam, Pharm.D., of Ally Bridge Group, Eric Crombez, M.D., Chief Medical Officer of Ultragenyx, and Jennifer King, Ph.D., former SVP of Business Development at Intellia Therapeutics and an expert in rare diseases and strategic partnerships. About EPI-321 EPI-321 is an investigational epigenetic therapy that aims to address the underlying molecular mechanisms of FSHD with a one-time dose. It has been granted FDA Fast Track, Rare Pediatric Disease, and Orphan Drug designations. Following intravenous administration, EPI-321 is directed to muscle tissue within a single AAV vector, which has been clinically validated for muscle delivery. Preclinical studies on EPI-321 have demonstrated its ability to robustly suppress pathological expression of the DUX4 gene and reduce muscle cell death. A first-in-human clinical trial of EPI-321 is planned for 2025. About Epicrispr Biotechnologies Epicrispr Biotechnologies is a biotechnology company pioneering gene-modulating therapies, leading with treatments for neuromuscular diseases. The company's proprietary Gene Expression Modulation System (GEMS) enables precise, durable control of gene expression, unlocking first-in-class treatments for previously untreatable conditions. Epicrispr's lead program, EPI-321 is in clinical trials for FSHD, and the company is advancing additional gene-modulating therapies. Epicrispr also has a research collaboration with Kite Pharma to develop next-generation CAR T-cell therapies. Learn more at or follow us on LinkedIn. About Ally Bridge Group Ally Bridge Group is a global healthcare investment firm focused on private and public high-impact life science innovation. Founded in 2013 by Frank Yu, the firm has led or co-led over $6 billion in healthcare transactions. The firm's mission is to generate superior risk-adjusted returns for investors guided by the core principle of selective investment in healthcare innovation that addresses unmet medical needs. Ally Bridge Group has offices in New York and Hong Kong. For more information, visit or follow us on LinkedIn. View source version on Contacts Investor ContactBenson Media ContactKimberly HaKKH Sign in to access your portfolio
